Nivolumab plus chemotherapy prolongs PFS in gastric, gastroesophageal junction cancer

The addition of nivolumab to first-line chemotherapy significantly improved PFS, but not OS, for patients with advanced or recurrent HER2-negative gastric and gastroesophageal junction cancer, according to phase 3 study findings.Results of the double-blind, randomized ATTRACTION-4 trial, presented at ESMO Virtual Congress 2020, also showed a higher objective response rate and more durable responses with the combination than with chemotherapy alone, researchers noted.“Nivolumab [Opdivo, Bristol Myers Squibb] has shown significant survival benefit for heavily pretreated patients withRead More

Share on facebook
Share on twitter
Share on linkedin